JP2021506907A - 高トリグリセライド血症の治療方法 - Google Patents

高トリグリセライド血症の治療方法 Download PDF

Info

Publication number
JP2021506907A
JP2021506907A JP2020534340A JP2020534340A JP2021506907A JP 2021506907 A JP2021506907 A JP 2021506907A JP 2020534340 A JP2020534340 A JP 2020534340A JP 2020534340 A JP2020534340 A JP 2020534340A JP 2021506907 A JP2021506907 A JP 2021506907A
Authority
JP
Japan
Prior art keywords
subject
patient
pemafibrate
renal dysfunction
hdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020534340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506907A5 (https=
Inventor
ゴードン ギャリー
ゴードン ギャリー
隆 大島
隆 大島
和人 末平
和人 末平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of JP2021506907A publication Critical patent/JP2021506907A/ja
Publication of JP2021506907A5 publication Critical patent/JP2021506907A5/ja
Priority to JP2023187862A priority Critical patent/JP2023181451A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020534340A 2017-12-21 2018-12-20 高トリグリセライド血症の治療方法 Pending JP2021506907A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023187862A JP2023181451A (ja) 2017-12-21 2023-11-01 高トリグリセライド血症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609048P 2017-12-21 2017-12-21
US62/609,048 2017-12-21
PCT/US2018/066976 WO2019126597A1 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023187862A Division JP2023181451A (ja) 2017-12-21 2023-11-01 高トリグリセライド血症の治療方法

Publications (2)

Publication Number Publication Date
JP2021506907A true JP2021506907A (ja) 2021-02-22
JP2021506907A5 JP2021506907A5 (https=) 2022-01-11

Family

ID=66995099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020534340A Pending JP2021506907A (ja) 2017-12-21 2018-12-20 高トリグリセライド血症の治療方法
JP2023187862A Pending JP2023181451A (ja) 2017-12-21 2023-11-01 高トリグリセライド血症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023187862A Pending JP2023181451A (ja) 2017-12-21 2023-11-01 高トリグリセライド血症の治療方法

Country Status (9)

Country Link
US (1) US20190224169A1 (https=)
EP (1) EP3727376A4 (https=)
JP (2) JP2021506907A (https=)
CN (1) CN111741753A (https=)
AU (1) AU2018393119B2 (https=)
CA (1) CA3085951C (https=)
MY (1) MY205171A (https=)
SG (1) SG11202005850VA (https=)
WO (1) WO2019126597A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024014524A1 (ja) * 2022-07-15 2024-01-18 興和株式会社 血中ｌｄｌコレステロール低下剤
WO2025069226A1 (ja) * 2023-09-26 2025-04-03 興和株式会社 ペマフィブラートを含有する医薬

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (ru) * 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
ES2752039T3 (es) * 2012-09-27 2020-04-02 Kowa Co Agente terapéutico para la dislipidemia
EA201790091A1 (ru) * 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"パルモディア（商標名）錠０．１ｍｇ", 医薬品インタビューフォーム, vol. 第１版, JPN6023002083, July 2017 (2017-07-01), pages 1 - 98, ISSN: 0005118916 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024014524A1 (ja) * 2022-07-15 2024-01-18 興和株式会社 血中ｌｄｌコレステロール低下剤
WO2025069226A1 (ja) * 2023-09-26 2025-04-03 興和株式会社 ペマフィブラートを含有する医薬

Also Published As

Publication number Publication date
US20190224169A1 (en) 2019-07-25
JP2023181451A (ja) 2023-12-21
MY205171A (en) 2024-10-04
AU2018393119A1 (en) 2020-07-23
CA3085951A1 (en) 2019-06-27
WO2019126597A1 (en) 2019-06-27
EP3727376A4 (en) 2021-07-21
AU2018393119B2 (en) 2022-08-25
SG11202005850VA (en) 2020-07-29
EP3727376A1 (en) 2020-10-28
CN111741753A (zh) 2020-10-02
CA3085951C (en) 2022-10-11

Similar Documents

Publication Publication Date Title
Seth et al. Allopurinol for chronic gout
Bommelaer et al. Oral curcumin no more effective than placebo in preventing recurrence of Crohn's disease after surgery in a randomized controlled trial
Nolan Metabolic complications associated with HIV protease inhibitor therapy
US11446282B2 (en) Methods of treating mixed dyslipidemia and hypertriglycertdemia
Xie et al. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study
JP2023181451A (ja) 高トリグリセライド血症の治療方法
JP2018536710A (ja) 混合型脂質異常症の治療
Eiland et al. Use of statins for dyslipidemia in the pediatric population
JP2018184463A (ja) スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
KR20180004263A (ko) 염증 또는 신경병성 통증의 치료 방법
AU2014353246A1 (en) Treatment of homozygous familial hypercholesterolemia
Bays et al. Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial
AIDS Clinical Trials Group A5148 Study Team et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148
Teramoto et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
JP7466534B2 (ja) 代謝性疾患及び／又はその臨床状態を抑制及び／又は処置するための組成物及び方法
TWI741379B (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
TWI651086B (zh) 用以治療或預防心血管疾病之膽固醇酯轉蛋白質(cetp)抑制劑及包含該抑制劑之醫藥組成物
Ballantyne et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study
US12377104B1 (en) Methods for treating a fatty liver disease
Aguilar-Salinas et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study
Yee et al. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication
US20230092776A1 (en) Methods of treating mixed dyslipidemia and hypertriglyceridemia
Yamashita et al. Efficacy for LDL-C–lowering and Safety of Pemafibrate Extended-release Formulation in Patients with Statin-intolerant Hypercholesterolemia: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group trial
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
Gonzalez-Campoy et al. Evaluation and treatment of atherogenic dyslipidemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230801